Bjurman Christian, Petzold Max, Venge Per, Farbemo Julia, Fu Michael L X, Hammarsten Ola
Department of Medicine, Sahlgrenska University Hospital, The Sahlgrenska Academy at the University of Gothenburg, SE-41345 Gothenburg, Sweden.
Centre for Applied Biostatistics, The Sahlgrenska Academy at the University of Gothenburg, SE-41345 Gothenburg, Sweden.
Clin Biochem. 2015 Mar;48(4-5):302-7. doi: 10.1016/j.clinbiochem.2015.01.008. Epub 2015 Jan 28.
Elevation of cardiac markers in patients with renal dysfunction has not been fully assessed reducing the diagnostic usefulness of these biomarkers.
To examine the effects of renal function and a medical record of cardiovascular disease on levels of cardiac biomarkers.
Serum samples were collected from 489 patients referred for GFR measurement using Cr51-EDTA or iohexol plasma clearance (measured GFR). The cardiac biomarkers Troponin T (hs-cTnT), Troponin I (hsTnI), N-Terminal pro-Brain Natriuretic Peptide (NTproBNP), Copeptin, Human Fatty Acid-Binding Protein (hFABP), as well as the kidney function biomarkers creatinine and cystatin C, were measured. Regression was used to analyse the relationship between biomarker levels and the glomerular filtration rate (GFR) between 15 and 90mL/min/1.73m(2).
Compared with normal kidney function, the estimated increases in the studied cardiac biomarkers at a GFR of 15mL/min/1.73m(2) varied from 2-fold to 15-fold but were not very different between patients with or without a medical record of cardiovascular disease and were most prominent for cardiac biomarkers with low molecular weight. hs-cTnT levels correlated more strongly to measured GFR and increased more at low GFR compared to hs-cTnI. For hFABP and NTproBNP increases at low kidney function were more correctly predicted by a local Cystatin C-based eGFR formula compared with creatinine-based eGFR (using the MDRD or CKD-EPI equations).
The extent of the elevation of cardiac markers at low renal function is highly variable. For hFABP and NTproBNP Cystatin C-based eGFR provides better predictions of the extent of elevation compared to the MDRD or CKD-EPI equations.
肾功能不全患者心脏标志物的升高尚未得到充分评估,这降低了这些生物标志物的诊断效用。
研究肾功能及心血管疾病病史对心脏生物标志物水平的影响。
收集489例因使用Cr51-EDTA或碘海醇血浆清除率(测量的肾小球滤过率)进行肾小球滤过率(GFR)测量而转诊患者的血清样本。检测心脏生物标志物肌钙蛋白T(高敏肌钙蛋白T)、肌钙蛋白I(高敏肌钙蛋白I)、N末端脑钠肽前体(NTproBNP)、 copeptin、人脂肪酸结合蛋白(hFABP)以及肾功能生物标志物肌酐和胱抑素C。采用回归分析15至90mL/min/1.73m²之间生物标志物水平与肾小球滤过率(GFR)的关系。
与肾功能正常相比,GFR为15mL/min/1.73m²时,所研究的心脏生物标志物估计升高幅度在2倍至15倍之间,有或无心血管疾病病史的患者之间差异不大,且分子量低的心脏生物标志物升高最为显著。与高敏肌钙蛋白I相比,高敏肌钙蛋白T水平与测量的GFR相关性更强,在低GFR时升高幅度更大。对于hFABP和NTproBNP,与基于肌酐的估算肾小球滤过率(使用MDRD或CKD-EPI方程)相比,基于胱抑素C的局部估算肾小球滤过率公式能更准确地预测肾功能低下时的升高情况。
肾功能低下时心脏标志物升高的程度差异很大。与MDRD或CKD-EPI方程相比,基于胱抑素C的估算肾小球滤过率能更好地预测hFABP和NTproBNP升高的程度。